Febuxostat

Limits on what this shows

• Null findings: Pulmonary hypertension mouse study: H2O2 not attenuated by febuxostat [9].
• At-risk subgroups: None identified. The two case reports involved people with existing mitochondrial disease [10].

Regulatory status

No mitochondrial statement in the label text read [1].

Population evidence

A PubMed listing of 9 records on febuxostat and mitochondrial function (cells, rodents, 2 patients, 1 review) reported protection in 8 and no effect in 1, with none reporting toxicity (listing text via a summarizing tool) [9]. Examples: cardiorenal syndrome rats and NRK-52E cells, febuxostat 30 mg/kg/day reversed oxidative stress and mitochondrial membrane potential changes (Int J Biol Sci 2025, listing text; the full article was not opened); human aortic valve endothelial cells at 5 to 10 uM had lower mitochondrial ROS (J Cardiovasc Pharmacol 2022); macrophage membrane potential depolarization prevented [8][9].

Mechanism

Named for the protective direction: less xanthine oxidase-derived oxidant stress and better purine salvage [8][9]. No mechanism for toxicity.

Direction

Reverse or neutral.

Counter-evidence held on record

Counter-evidence and confounding These studies were designed to test benefit, not mitochondrial toxicity, so a lack of toxicity reports is an absence of signal, not a safety test. Findings are from preclinical models. The liver entry is separate; label hepatotoxicity has no mitochondrial mechanism in any source opened. Framing caution Not a mitochondrial benefit or harm claim. Reverse-direction preclinical context only.

Limits on what this shows

• Null findings: PRIZE direct MDA-LDL null [6]. One pulmonary hypertension mouse study found H2O2 was not attenuated by febuxostat [9].
• At-risk subgroups: Not applicable to a reverse-direction finding. Findings come from hemodialysis and atherosclerosis cohorts.

Regulatory status

Not mentioned in the label text read [1].

Population evidence

Randomized, double-blind, placebo-controlled trial, 57 hemodialysis patients with endothelial dysfunction, febuxostat 40 mg for 2 months: serum malondialdehyde fell and superoxide dismutase rose in the febuxostat group, with no significant change in placebo; p values not given in the abstract-level read [5]. PRIZE randomized-trial subanalysis, 383 patients (febuxostat n=200, control n=183), asymptomatic hyperuricemia with carotid atherosclerosis, febuxostat 10 to 60 mg daily for 24 months: direct MDA-LDL did not differ between groups; the MDA-LDL/LDL-C ratio was possibly lower with febuxostat [6].

Mechanism

Named, not measured in the human trials: xanthine oxidase generates reactive oxygen species during purine oxidation, and the rodent and cell studies attribute their oxidative-stress findings to its inhibition [7][9]. Preclinical records (heart, colon, lung, kidney, liver in rats, mice and rabbits, plus human glomerular endothelial cells) report lower malondialdehyde and higher superoxide dismutase or glutathione, Tier B [7].

Direction

Reverse. No deficiency or depletion is claimed.

Counter-evidence held on record

Counter-evidence and confounding The 57-patient trial is small, short, abstract-level here and in dialysis patients; marker changes may reflect urate lowering rather than a direct antioxidant effect. The larger trial did not confirm the primary marker. The control group of the larger trial was not described as placebo in the summary read. Framing caution Not an antioxidant benefit claim and not a basis to advise antioxidant supplements. Reverse-direction context only.

Limits on what this shows

• Null findings: Allopurinol: no effect on iron absorption, storage or incorporation [21]. Hemoglobin data are in the oxygen delivery entry and are not repeated as iron evidence.
• At-risk subgroups: None identified.

Regulatory status

No iron statement in the label text read; iron appears only as ferric oxide yellow, a tablet coating excipient, which is not a nutrient finding [1].

Population evidence

Febuxostat-specific iron measures (ferritin, transferrin saturation, hepcidin): none found. Allopurinol, not febuxostat: a ferrokinetic study of 9 patients with gout or hyperuricemia, control period versus allopurinol, found no measurable effect on iron absorption, storage or red-cell incorporation [21]; a 1977 rat record reported allopurinol did not alter organ iron content (listing-level read only) [22]. A broader PubMed query on febuxostat with iron-overload terms returned only general iron-overload papers and no febuxostat record, which is an uninformative query, not a clean null [22].

Mechanism

None named for febuxostat. A link between xanthine oxidase-derived radicals and iron release from stores was an angle in the review brief and was not located in any febuxostat source opened.

Class cohort test

CLASS EXTRAPOLATION. The cohorts in [21] and [22] were allopurinol only; febuxostat was NOT in either cohort, so both are Tier C for this drug and capped at yellow. Febuxostat is a non-purine inhibitor and allopurinol is a purine analogue, so the null may not transfer. Both findings are nulls, so the class gives no supporting signal, only the absence of one.

Direction

Neutral. Neither depletion nor retention is claimed.

Counter-evidence held on record

Counter-evidence and confounding Small, old, allopurinol-only studies; iron status in gout patients is also shaped by CKD, inflammation and diet. Framing caution No iron supplementation or restriction is recommended by this entry. Iron deficiency is not anemia and anemia is not iron deficiency (Hard Rule 2).

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or C source was opened that supports even a yellow grade, and no circulating copper claim for febuxostat was found to rebut. A disclosed gap, not a finding of safety. Copper is a separate entry from Iron (Hard Rule 7).

What was searched

Label keyword check (copper absent) [1]; Drugs.com food and side-effect pages [27][28]. Repair pass 2026-10-07: PubMed search pages "febuxostat copper" (0 results) and "febuxostat ceruloplasmin" (0 results), both opened and confirmed by the page's zero-result message [29]. The earlier "febuxostat copper" and "febuxostat trace elements zinc copper serum" listings (format=pubmed) had returned 404; the verified zero-result pages show that a 404 on that endpoint corresponded to zero hits for the copper query. The allopurinol sibling dossier records an in vitro copper complexation finding for allopurinol; those sources were not opened here and febuxostat was not tested, so nothing is borrowed.

Channel outcomes

PubMed: verified zero febuxostat records for copper and ceruloplasmin. Web search: budget exhausted, so a circulating-claim check beyond Drugs.com was not possible. A "febuxostat trace elements" page query was rate-limited (429) and not read. Genuine gap in the indexed literature for copper; the circulating-claim audit remains tooling-limited.

Limits on what this shows

• Null findings: Four hyperuricemia animal papers surfaced by searches had no febuxostat arm (allopurinol or no drug) and give no febuxostat result; a fifth, a rat paper, used febuxostat only as a pharmacokinetic probe and did not compare microbiota in treated versus untreated animals [13].
• At-risk subgroups: None identified.

Regulatory status

Not mentioned in the label text read [1].

Population evidence

Human cohort, J Genet Genomics 2021: 38 febuxostat-treated gout patients, 38 untreated gout patients and 26 healthy controls; restriction of biodiversity in untreated gout "partly restored by febuxostat" (PubMed listing text via a summarizing tool; OpenAlex held no abstract; design details, taxa and effect sizes not read) [11][12]. Human cohort, J Microbiol 2022: 48 febuxostat-treated gout patients (28 controlled, 20 uncontrolled urate) and 17 healthy controls; Prevotella was enriched in uncontrolled patients and Bifidobacterium in healthy controls, which compares urate control states and does not isolate a drug effect (listing text only) [11]. A 160-patient probiotic trial had febuxostat in every arm and cannot attribute anything to the drug [11]. A rat CRF study had a febuxostat comparator arm with dysbiosis remodeling, listing-level only [11].

Mechanism

Not established. The cohorts cannot separate febuxostat from lower urate or better gout control.

Direction

Reverse or restorative relative to untreated gout. No SCFA or functional measures were read.

Counter-evidence held on record

Counter-evidence and confounding Confounding by indication and disease is presumed (Hard Rule 6): gout itself is linked to dysbiosis in these cohorts. Design (cross-sectional versus longitudinal) was not confirmed from the listing text, and diet, comorbidity and co-medication are unknown here. Framing caution Not a microbiome-harm claim and not a probiotic recommendation. A background statement in another paper that febuxostat lowered Lactobacillus and Bifidobacterium is untraced and is addressed under Fails verification.

Limits on what this shows

• Null findings: Hemoglobin: no difference versus allopurinol in transplant recipients [18]; stable over 16 months in a 9-patient switch study [17].
• At-risk subgroups: Label: hematologic reactions are rare and have no defined risk group in the text read. Concomitant azathioprine or mercaptopurine is contraindicated because 6-mercaptopurine exposure rises, a route to marrow toxicity that is a drug interaction, not a nutrient effect [1].

Regulatory status

Label sec 6.1: anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia and thrombocytopenia reported in under 1% of clinical trial patients; anemia is not in the table of reactions at 1% or more; agranulocytosis and eosinophilia in postmarketing reports [1]. A Tier D page lists hemoglobin decrease at 0.1 to 1%, red cell count decrease as rare and anemia with frequency not reported [28].

Population evidence

Randomized trial of benzbromarone versus febuxostat in 66 hyperuricemic CKD patients (33 per group): hemoglobin increased significantly in both groups (p under 0.05), and the authors suggested febuxostat could raise hemoglobin; with no placebo arm and the comparator also rising, the rise is not attributable to febuxostat [15][16]. Meta-analysis of 7 observational studies (367 kidney transplant recipients), febuxostat versus allopurinol: no significant difference in hemoglobin [18]. Nine hemodialysis patients switched from allopurinol to febuxostat 100 mg daily: hemoglobin, hematocrit and platelets stable through 16 months [17]. A 2026 meta-analysis in transplant recipients reported no hemoglobin result in its abstract and is not relied on [20]. Sickle cell mouse model, febuxostat 10 mg/kg/day for 10 weeks: higher hematocrit and cellular hemoglobin and lower cell-free hemoglobin, read by the authors as less hemolysis (the fetch tool and PubMed listing disagreed on the haptoglobin wording, so only the two consistent statements are used) [19].

Mechanism

None named for the label cytopenias. Human and rodent red cells reportedly show no xanthine oxidase activity (title-level reading only) [24], so no direct red-cell target is established. The mouse hemolysis result concerns a disease model with elevated xanthine oxidase and is not generalizable to people without it.

Direction

Neutral to reverse. This is an adverse-reaction flag and an outcome entry (Hard Rule 2): anemia is not iron deficiency and no nutrient was measured as the cause.

Counter-evidence held on record

Counter-evidence and confounding The label frequency is under 1% and is unadjusted for gout, CKD or other causes of anemia. Active-comparator trials (allopurinol or benzbromarone) do not test febuxostat against non-use. Study populations (CKD, transplant, dialysis) have baseline anemia from other causes. Framing caution A CBC prompt for symptoms, not a deficiency claim. Do not infer iron or B12 deficiency from a low hemoglobin on febuxostat; the cause is usually the underlying disease.

Limits on what this shows

• Null findings: No ATP-lowering finding was seen in any febuxostat record retrieved.
• At-risk subgroups: Not applicable.

Regulatory status

No ATP or energy-metabolism statement in the label text read [1].

Population evidence

No human tissue ATP measurement on febuxostat alone was found. Case reports: 2 patients with mitochondrial disease treated with febuxostat plus inosine (cardiomyopathy: BNP lowered 31%; diabetes: insulinogenic index raised 3.1-fold, listing text); febuxostat cannot be separated from inosine and no ATP value was read [9][10]. Preclinical Tier B: in mouse and human macrophages, nigericin lowered ATP about 60% and febuxostat (200 uM) restored ATP, total adenylates and basal respiration (Sci Rep 2019, abstract-level) [8]; a hypoxic mouse brain study reported higher energy charge and ATP and lower ATP catabolites with febuxostat, described as more potent than allopurinol (Brain Res 2025, listing text) [9]; febuxostat ameliorated rotenone-induced ATP exhaustion in Neuro2a cells (PLoS One 2017, listing text) [9].

Mechanism

Named: blocking oxidation of hypoxanthine leaves it available for purine salvage to re-form adenine nucleotides [8][9]. The in vitro concentration is not reconciled to human plasma exposure in this dossier.

Direction

Reverse. Not a depletion.

Counter-evidence held on record

Counter-evidence and confounding Cell and animal models with supraphysiologic or disease-specific conditions; one cell study used 200 uM. Absence of an ATP-lowering report is not evidence of safety. Framing caution Do not use this entry to claim energy benefits or to suggest purine supplements such as inosine; the single human report combined the two.